0R2S.L - Stryker Corporation

LSE - LSE Delayed Price. Currency in USD
-5.04 (-1.81%)
At close: 05:50PM BST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close278.42
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume4,182
Market Cap1.017B
Beta (5Y Monthly)0.95
PE Ratio (TTM)0.52
EPS (TTM)5.26
Earnings DateJul 24, 2023 - Jul 28, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 0R2S.L

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      HLN or SYK: Which Is the Better Value Stock Right Now?

      HLN vs. SYK: Which Stock Is the Better Value Option?

    • Zacks

      Why Is Stryker (SYK) Down 7.6% Since Last Earnings Report?

      Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    • Zacks

      Stryker's (SYK) Q Guidance Successful in First Surgery

      Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

    • Zacks

      The Zacks Analyst Blog Highlights Apple, Chevron, Accenture, Broadcom and Stryker

      Apple, Chevron, Accenture, Broadcom and Stryker are included in this Analyst Blog.

    • Zacks

      Top Analyst Reports for Apple, Chevron & Accenture

      Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Chevron Corporation (CVX) and Accenture plc (ACN).

    • Zacks

      Here's Why You Should Retain Stryker (SYK) Stock for Now

      Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

    • Business Wire

      Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

      LEESBURG, Va., May 24, 2023--Stryker launches Q Guidance System with Cranial Guidance Software, providing groundbreaking planning and guidance capabilities.

    • Zacks

      3 Healthcare Trends to Ride for Longevity

      Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.

    • Barrons.com

      Healthcare Stocks Are on Sale. Pfizer and Stryker Have Strong Growth Prospects.

      Healthcare has had the greatest earnings growth of any sector since the mid-1980s. Why Pfizer and Stryker are two favorite stocks of the Jensen Quality Growth fund.

    • Motley Fool

      Which Is the Safer Dividend Stock: Stryker or Medtronic?

      Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend income they offer to investors. Overall, Stryker's business is quite stable: It makes medical equipment, medical instruments, and surgical robotics for healthcare systems worldwide, and there isn't much in the way of rapidly shifting demand for its major segments.​​​​ But it can reliably generate growth by investing in research and development (R&D) to make incremental improvements to its existing products, even if that growth is unlikely to be rapid due to the slow-growing nature of its markets. For example, developing more-advanced hip replacement products for use with its surgical robot system probably won't make investors rich overnight, but it'll keep the top and bottom lines expanding.

    • GlobeNewswire

      Stryker declares a $0.75 per share quarterly dividend

      Kalamazoo, Michigan, May 10, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable July 31, 2023 to shareholders of record at the close of business on June 30, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company

    • Zacks

      Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet

      Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.

    • Zacks

      4 Medical Products Stocks to Capitalize on the Industry's Recovery

      Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

    • The Wall Street Journal

      Medical Device Maker Stryker Faces New Bribery Concerns

      The medical-device maker disclosed an investigation by U.S. authorities into potential violations of antibribery law, the third such probe into the company in the past decade.

    • Motley Fool

      Got $5,000? Buy These 2 Stalwart Stocks and Hold Them Forever

      Packing your portfolio with risky hyper-growth stocks might make you feel like a genius during a bull market, but when there's a downturn, your smile just might get turned upside down. As exciting as seeing rapidly rising share prices might be, your portfolio needs to be well-diversified, and that means you need a few companies that are stable in the face of turmoil, not to mention being capable of delivering some growth all the time. Thermo Fisher Scientific (NYSE: TMO) is a sturdy stock that's fit for holding for decades because it's one of the businesses that makes the entire biopharma sector run.

    • Benzinga

      What's Going On With Stryker Stock Today

      The orthopedic and surgical device giant Stryker Corporation (NYSE: SYK) stock is trading lower despite reporting Q1 earnings beat and an upbeat outlook. It reported Q1 sales of $4.80 billion, up 11.8% Y/Y (+14% in constant currency), beating the consensus of $4.56 billion. Organic net sales increased 13.6% in the quarter, including 12.9% from increased unit volume and 0.7% from higher prices. MedSurg and Neurotechnology net sales of $2.7 billion increased by 11.0% (+13.1% in constant currency).

    • Zacks

      BAX vs. SYK: Which Stock Should Value Investors Buy Now?

      BAX vs. SYK: Which Stock Is the Better Value Option?

    • PR Newswire

      Stryker completes acquisition of Cerus Endovascular

      Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular's CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker's current portfolio of aneur

    • Zacks

      Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

      Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

    • Zacks

      Stryker (SYK) Tops Q1 Earnings and Revenue Estimates

      Stryker (SYK) delivered earnings and revenue surprises of 7% and 4.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

    • Reuters

      Stryker lifts profit forecast on robust demand for devices

      Medical technology company Stryker Corp on Monday raised its full-year profit forecast, citing stronger demand for the company's surgical devices. Device makers, lately, have been reporting a recovery in sales as staff shortages ease and procedure volumes pick up in hospitals. Last week, peer Edwards Lifesciences Corp raised its sales and profit forecasts for 2023, citing strong demand for the company's artificial heart valves.

    • GlobeNewswire

      Stryker reports first quarter 2023 operating results

      Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2023: First Quarter Results Reported net sales increased 11.8% to $4.8 billionOrganic net sales increased 13.6%Reported operating income margin of 15.4%Adjusted operating income margin(1) contracted 70 bps to 21.1%Reported EPS increased 83.3% to $1.54Adjusted EPS(1) increased 8.6% to $2.14 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant

    • Motley Fool

      3 Medical Device Stocks Outpacing the Healthcare Industry This Year

      Medical device makers are outperforming the general healthcare market so far this year as supply issues ease and the volume of medical procedures is increasing. Three examples are Medtronic (NYSE: MDT), Edwards Lifesciences (NYSE: EW), and Stryker (NYSE: SYK), each of which is up more than 15% this year. The rest of the healthcare industry, on the other hand, has mostly seen its shares decline.

    • Motley Fool

      These 3 Stocks Might Be Getting a Little Too Expensive

      Its valuation should be very attractive or at least reasonable -- otherwise you may buy at such a steep valuation that the stock will be as likely to retreat as to advance. Here are three promising companies whose stocks seem to have gotten ahead of themselves. Hershey (NYSE: HSY) has been a sweet investment for many people, outpacing the S&P 500 over the past decade with an average annual total return of roughly 14% versus 12% for the benchmark index.

    • Zacks

      Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

      Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.